Naegele A., Christophsbad Gppingen, Department of Neurology
The American College of Rheumatologys 2025 annual conference (ACR Convergence 2025) added to this picture, with data suggesting that patients on GLP-1 drugs had fewer rheumatic disease flares and that those with osteoarthritis saw greater improvements in pain and function compared to those on SGLT2 inhibitors, another diabetes drug class [11]
UBXD18, Ubiquitin regulatory X (UBX) domain-containing protein 18
Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of tlr-4 and cd14
BPC 157 to peptyd, ktry w ostatnich latach zyskuje na popularnoci w rodowisku sportowym i medycznym ze wzgldu na swoje potencjalne waciwoci regeneracyjne
A phase I clinical trial was conducted with a long-acting amylin analogue developed by Zealand Pharma in cooperation with Boehringer Ingelheim in 2018, but the collaboration on this analogue was terminated in 2020 (144, 145)
